oracle health sciences global business unit strategy
DESCRIPTION
Oracle Health Sciences Global Business Unit Strategy. Steve Rosenberg Senior Vice President and General Manager Oracle Health Sciences Global Business Unit. Clinical R&D - What hasn’t Changed…. Improved Outcomes & Care. Greater Safety. Reduced Costs. Streamlined R&D. - PowerPoint PPT PresentationTRANSCRIPT
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Oracle Health Sciences Global Business Unit Strategy
Steve Rosenberg Senior Vice President and General ManagerOracle Health Sciences Global Business Unit
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Safe Harbor StatementThe following is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle’s products remains at the sole discretion of Oracle.
2
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Clinical R&D - What hasn’t Changed…
Improved Outcomes & Care Greater Safety
Reduced CostsStreamlined R&D
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Clinical R&D - What Continues to Change …
Science & Technology
Clinical R&D ProcessPatient Engagement
Clinical R&D Landscape
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 5
Oracle Health Sciences
Life Sciences
Healthcare
Continuum
Accelerate clinical developmentSupport entire drug safety lifecycleEnable clinical data aggregation
Power enterprise healthcare analytics Enable provider/payer integrationDrive personalized medicine
The movement from clinical research to clinical careDevelop collaboration networks for providers
and life sciences companies
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 6
Life Sciences
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Optimizing Clinical Research & Development
HEALTH SCIENCES CLOUD
Safety Lifecycle
Analytics and Insights
Signal Detection
Randomization & Trial Supply Management
Clinical Data Aggregation& Reporting
Comprehensive Electronic Data Capture
Trial Management& Monitoring
Planning & Budgeting
7
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Oracle Life Sciences
Broadest, best-of-breed applications
Focus on integration
The highest standards of scalability, security, and privacy
8
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Recent Oracle Life Sciences InnovationsMOBILITYINFORM, CRA & ANALYTICS
KEY PRODUCT & THIRD PARTY INTEGRATIONS
DATA MANAGEMENTWORKBENCH
INFORM ADVANCED MOLECULAR ANALYTICS
MEDICATION ADHERENCE (PROTEUS)
CLINICAL MONITORING CLOUD
REAL-WORLD SAFETY SURVEILLANCE & COMPARATIVE EFFECTIVENESS
RISK BASED MONITORING
9
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
• FDA-approved ingestible sensors
• Captures the body’s physiologic responses and behaviors
• Sends digital health information to a mobile app
• Oracle’s clinical trial applications customers have exclusive access to real-time data on therapeutic use
Medication Adherence
8
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Medication compliance insight
Better dose selection
Fewer Phase III failures
Improved drug safety
Medication Adherence
9
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
DEEP-ROOTED COMMITMENTTO DRIVING CLINICAL R&D PROCESS
OPTIMIZATIONAND ANALYTIC INSIGHTS
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 13
Healthcare
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Healthcare Providers are Facing:
Patient engagement and compliance
Care coordination Population health Precision medicine
Immediate Focus: Operational effectiveness Risk-based revenue
Evolves Over Time:
Changing business models and risk shifting
Margin pressure – cost, revenue, and volume
Consolidation pressure
Increased complexity in regulation
Aging population and management of chronic diseases
14
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Clinical Finance Human Resources Supply Chain Claims Genomics Research Clinical Trials 3rd Party Data
Client Developed Apps
Oracle Enterprise Healthcare
Analytics
Third Party Apps
Oracle Apps
Analyze NormalizeAggregate
Enabling Value ThroughMultiple & DisparateData Sources
Comprehensive Healthcare Data Model
Combines Clinical and OMICS Data
Data Governance
Productized Data Loaders Leverages Oracle Technology Application Choice
Powering Enterprise Healthcare Analytics
15
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 16
Continuum
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Delivers:
Biomarker discovery
Protocol validation and patient recruitment
Patient stratification
Safety and comparative effectiveness
Population health
Precision medicine
Harnessing Big Data for Life Sciences & Healthcare• Volume and availability of data continues to increase
• Data will have various strengths and significance
• Velocity of data is coming in faster than ever before
• Who better than Oracle to attack this?Sensors
Petabytes of information
Velocity of real-time data
Genomics
Variety of data sourcesReal-World Data
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Delivers:
Biomarker discovery
Protocol validation and patient recruitment
Patient stratification
Safety and comparative effectiveness
Population health
Precision medicineSensors
Petabytes of information
Velocity of real-time data
Genomics
Variety of data sourcesReal-World Data
Oracle Health
Sciences
Harnessing Big Data for Life Sciences & Healthcare
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 19
Effectiveness of Most Drugs
Major Drug Drug Effectiveness Cost of Ineffectivenessto Healthcare System
Source: The Personalized Medicine Coalition
Hypertension DrugsACE Inhibitors
10-30% $390 million – $1.2 billion
Anti Depressant DrugsSSRIs
20-50% $2.3 billion – $5.8 billion
Cholesterol Drugs Statins
30-70% $3.8 billion – $8.8 billion
Asthma Drugs Beta-2-agonists
40-70% $560 million – $1.0 billion
Heart Failure Drugs Beta Blockers
15-25% $345 million – $575 million
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Targeted treatments
More effective trials
Faster time to market
Improved safety
Dramatically lower costs
CURRENT TRANSFORMATION
Combining Clinical and OMICS data
Improving Population Health and Patient Outcomes
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
Healthcare Provider Participants
Life Sciences Participants While Ensuring:
Full control of de-identified data
Protection of Institutional IP
Respect for patient consent
Full HIPAA compliance
Oracle Health Sciences Network
Cloud-Based Collaborative R&D
Network Participants Include:
21
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 22
Why Oracle Health Sciences?
COMMITTED INVESTMENT IN LIFE SCIENCES & HEALTHCARE
INDUSTRIAL STRENGTH CAPABILITY
DEEP & BROAD DATA MANAGEMENT
BEST-OF-BREED TECHNOLOGY
UNMATCHED DOMAIN EXPERTISE
INNOVATION & TRANSFORMATION
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |
FROM PIPELINE TO PATIENTOPTIMIZING AND TRANSFORMING LIFE SCIENCES AND HEALTHCARE